Tenaya Therapeutics Inc. Common Stock (TNYA)
Stock · NASDAQ · Health Care
$0.3717as of 10/16/2026
Price chart
Active signals
TNYA Signal Track Record
How signals performed across all stocks →What TNYA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -4.1% | 42% | September 24, 2026 |
| Bollinger Band BreakdownActive now | 20 | -6.5% | 35% | September 24, 2026 |
| Bollinger Band Breakout | 18 | -1.3% | 50% | July 2, 2026 |
| 200-Day Moving Average TouchActive now | 5 | -22.3% | 20% | August 26, 2025 |
| Any 20-session window (baseline) | -7.9% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TNYA
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, wh…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 70
- Website
- www.tenayatherapeutics.com/
Fundamentals
- 1-day range
- $0.3703$0.417
- Market cap
- $157.50M
- P/E (trailing)
- —
- P/E (forward)
- -0.97
- EPS (trailing)
- $-0.53
- Dividend yield
- —
- Beta
- 2.87
- Avg. volume
- 2.59M
Forecasts
5 analyst ratings
Tenaya Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- CRDLCardiol Therapeutics Inc. Class A Common Shares$1.1▼ 4.35%Market cap $156.77MP/E —$1.23$3.23
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| CRDL Cardiol Therapeutics Inc. Class A Common Shares | $156.77M | — | $1.1 | ▼ 4.35% | $1.23$3.23 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeekingAlpha · 9/17/2026
- Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyYahoo · 9/14/2026
- FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Faraz Ali · September 10, 2026 · Grant122.0K
- Whittemore Tingley · September 10, 2026 · Grant293.0K
- Whittemore Tingley · September 10, 2026 · Grant49.0K
- Faraz Ali · September 10, 2026 · Grant732.5K
- Whittemore Tingley · August 17, 2026 · Sale2.3K @ $0.7098
- Whittemore Tingley · August 17, 2026 · Sale1.9K @ $0.7098
- Whittemore Tingley · August 17, 2026 · Sale1.6K @ $0.7098
- Faraz Ali · August 17, 2026 · Sale7.4K @ $0.7097
- Faraz Ali · August 17, 2026 · Sale5.0K @ $0.7097
- Faraz Ali · August 17, 2026 · Sale4.0K @ $0.7098
- Faraz Ali · August 17, 2026 · Sale5.8K @ $0.7097
- Eric J. Hyllengren · July 13, 2026 · Grant1.65M
- Karah Herdman Parschauer · May 28, 2026 · Grant120.0K
- Walsh Jeffrey T. · May 28, 2026 · Grant120.0K
- Williams R Sanders · May 28, 2026 · Grant120.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 53.57M
- Total value held
- $36.12M
- Institutional holders
- 100
- Unknown8.48M
- Unknown5.46M
- Unknown4.38M
- Unknown4.29M
- Unknown3.71M
- Unknown3.70M
- Unknown2.71M
- Unknown2.00M
- Unknown2.00M
- Unknown1.56M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tenaya Therapeutics noted among health‑care stocks moving intraday
Tenaya Therapeutics was listed among twelve health‑care stocks that showed notable intraday movement on Wednesday, according to Benzinga. The activity reflects broader sector momentum and comes while the stock is in oversold territory (RSI 19.6) and near its $0.68 support level.
Tenaya Therapeutics noted among health‑care stocks moving intraday. Tenaya Therapeutics was listed among twelve health‑care stocks that showed notable intraday movement on Wednesday, according to Benzinga. The activity reflects broader sector momentum and comes while the stock is in oversold territory (RSI 19.6) and near its $0.68 support level.